Penumbra, Inc. (PEN)
| Market Cap | 12.82B |
| Revenue (ttm) | 1.40B |
| Net Income (ttm) | 177.69M |
| Shares Out | 39.32M |
| EPS (ttm) | 4.52 |
| PE Ratio | 72.12 |
| Forward PE | 64.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 312,937 |
| Open | 328.48 |
| Previous Close | 327.98 |
| Day's Range | 325.76 - 328.73 |
| 52-Week Range | 221.26 - 362.41 |
| Beta | 0.84 |
| Analysts | Hold |
| Price Target | 360.14 (+10.48%) |
| Earnings Date | Apr 30, 2026 |
About PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ... [Read more]
Financial Performance
In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PEN stock is "Hold." The 12-month stock price target is $360.14, which is an increase of 10.48% from the latest price.
News
New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute int...
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decembe...
Boston Scientific announces results for fourth quarter and full year 2025
MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported b...
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach
Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions i...
Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.
The cash-and-stock acquisition values Penumbra at $374 a share.
Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments
Penumbra's stock was up about 14% after the deal was announced Thursday morning.
Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock
Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Boston Scientific to buy Penumbra in deal valued at $14.5 billion
Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth ...
Boston Scientific announces agreement to acquire Penumbra, Inc.
Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, ...
Penumbra Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant growth is expected from both thrombectomy and embolization, with new manufacturing in Costa Rica and strong clinical data from the STORM-PE trial driving adoption. The coil business is now a major growth driver, and margins are set to expand above 70% next year.
Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P.
Penumbra Transcript: Piper Sandler 37th Annual Healthcare Conference
Strong Q3 growth was driven by a focused sales force and the successful launch of Ruby XL. Clinical data from the STORM-PE trial is accelerating protocol changes and market adoption for mechanical thrombectomy, while new product iterations and regulatory progress position the company for continued expansion.
Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on We...
Penumbra Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 17.8% year-over-year to $354.7M, led by strong U.S. thrombectomy and embolization growth, with gross margin expanding to 67.8%. Full-year revenue guidance was raised, and STORM-PE trial results are expected to drive further adoption of CAVT technology.
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden ...
Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thro...
Penumbra Transcript: Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025
A landmark randomized trial demonstrated that mechanical thrombectomy (CABT) is superior to anticoagulation alone for intermediate high-risk pulmonary embolism, with significant improvements in heart strain and comparable safety. The results are expected to drive changes in clinical guidelines and expand adoption through education and multidisciplinary collaboration.
Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
ALAMEDA, Calif. , Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM ...
Penumbra Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Leadership transitions and team specialization are driving focus on key growth areas. The STORM-PE trial could shift PE treatment paradigms, while new products like Thunderbolt and Ruby XL are set to accelerate adoption and innovation. Strong U.S. and improving international markets support a positive growth outlook.
New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif. , Sept. 9, 2025 /PRNewswire/ -- The American Ve...
Penumbra Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Management outlined a strong outlook driven by innovation, new product launches, and clinical data, with Storm-PE and Thunderbolt as major upcoming catalysts. Margin expansion and reduced China headwinds are expected to support growth, while embolization and stroke franchises continue to gain share.